• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环上皮-间充质转化相关 miRNA 是卵巢癌有前途的生物标志物。

Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer.

机构信息

Department of Human Genetics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

出版信息

J Biotechnol. 2019 May 20;297:58-65. doi: 10.1016/j.jbiotec.2019.04.003. Epub 2019 Apr 3.

DOI:10.1016/j.jbiotec.2019.04.003
PMID:30953675
Abstract

Ovarian cancer is the fifth most common cause of cancer death among women that is mostly due to the difficulty of early diagnosis. Circulating miRNAs proved to be reliable biomarkers in various cancers. We screened 9 miRNAs, which are involved in epithelial-mesenchymal transition, in the plasma samples of patients with malignant (n = 28) or non-malignant (n = 12) ovarian tumors and disease-free healthy volunteers (n = 60) by qRT-PCR. The expression levels of miR200a, miR200b, miR200c, miR141, miR429, miR203a, miR34b (p < 0.001) and miR34a (p < 0.01) were significantly higher in the malignant samples than in healthy controls. MiR203a, miR141 (p < 0.01), miR200a and miR429 (p < 0.05) levels were also higher in malignant compared to non-malignant samples. ROC-AUC was the highest in the case of miR200c: 0.861 (95%CI = 0.776-0.947). Spearman's rank correlation analysis revealed positive correlation between the plasma levels of the studied miRNAs that was the highest between miR200b and miR200c (r = 0.774; p < 0.001). Target analysis also suggested tight interaction between these miRNAs in the regulation of cancer development. The agreement of diagnostic tests based on miRNA levels and the standard CA125 or HE4 was weak according to Cohen's kappa values. We conclude that miR200 family members, miR34b and miR203a might be promising complementary biomarkers in ovarian cancer.

摘要

卵巢癌是女性癌症死亡的第五大常见原因,主要是由于早期诊断困难。循环 miRNA 已被证明是各种癌症中可靠的生物标志物。我们通过 qRT-PCR 筛选了 28 例恶性和 12 例非恶性卵巢肿瘤患者以及 60 例无病健康志愿者血浆样本中的 9 个参与上皮间质转化的 miRNA。miR200a、miR200b、miR200c、miR141、miR429、miR203a、miR34b(p<0.001)和 miR34a(p<0.01)在恶性样本中的表达水平明显高于健康对照组。miR203a、miR141(p<0.01)、miR200a 和 miR429(p<0.05)在恶性样本中也高于非恶性样本。miR200c 的 ROC-AUC 最高:0.861(95%CI=0.776-0.947)。Spearman 等级相关分析显示,研究中 miRNA 的血浆水平呈正相关,miR200b 和 miR200c 之间的相关性最高(r=0.774;p<0.001)。靶分析还表明,这些 miRNA 之间在癌症发展的调节中存在紧密的相互作用。根据 Cohen 的 kappa 值,基于 miRNA 水平和标准 CA125 或 HE4 的诊断测试的一致性较弱。我们得出结论,miR200 家族成员、miR34b 和 miR203a 可能是卵巢癌有前途的互补生物标志物。

相似文献

1
Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer.循环上皮-间充质转化相关 miRNA 是卵巢癌有前途的生物标志物。
J Biotechnol. 2019 May 20;297:58-65. doi: 10.1016/j.jbiotec.2019.04.003. Epub 2019 Apr 3.
2
Screening of Circulating MicroRNAs as Potential Biomarkers for the Diagnosis of Ovarian Cancer.循环 microRNAs 作为卵巢癌诊断潜在生物标志物的筛选。
Dis Markers. 2019 Aug 4;2019:7541857. doi: 10.1155/2019/7541857. eCollection 2019.
3
Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.血清miR-193a-5p、HE4和CA125诊断模型提高上皮性卵巢癌的诊断效能。
Pathol Oncol Res. 2018 Oct;24(4):739-744. doi: 10.1007/s12253-018-0392-x. Epub 2018 Mar 8.
4
The Cell-Free Expression of MiR200 Family Members Correlates with Estrogen Sensitivity in Human Epithelial Ovarian Cells.miR200 家族成员的无细胞表达与人上皮性卵巢细胞的雌激素敏感性相关。
Int J Mol Sci. 2020 Dec 20;21(24):9725. doi: 10.3390/ijms21249725.
5
Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.组织CA125和HE4基因表达水平在鉴别盆腔良恶性肿块方面具有更高的准确性。
Asian Pac J Cancer Prev. 2016;17(1):323-33. doi: 10.7314/apjcp.2016.17.1.323.
6
A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer.循环微小RNA-125b作为上皮性卵巢癌诊断和预后生物标志物的初步研究
Int J Gynecol Cancer. 2017 Jan;27(1):3-10. doi: 10.1097/IGC.0000000000000846.
7
Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.HE4 和 CA125 标志物在 I 型和 II 型上皮性卵巢癌中的诊断性能。
Gynecol Oncol. 2013 Oct;131(1):52-8. doi: 10.1016/j.ygyno.2013.07.094. Epub 2013 Jul 25.
8
Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.血清miR-200a、miR-200b和miR-200c作为上皮性卵巢癌候选生物标志物的表达及其与临床病理特征的关联。
Clin Transl Oncol. 2015 Oct;17(10):779-87. doi: 10.1007/s12094-015-1303-1. Epub 2015 Jun 11.
9
The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients.循环 microRNA-145 在卵巢上皮性癌患者中的有希望的特征。
Microrna. 2020;9(1):49-57. doi: 10.2174/2211536608666190225111234.
10
Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.HE4、CA125及卵巢恶性肿瘤风险算法在韩国女性卵巢癌预测中的比较
J Korean Med Sci. 2015 Dec;30(12):1777-83. doi: 10.3346/jkms.2015.30.12.1777. Epub 2015 Nov 30.

引用本文的文献

1
Circulating microRNAs as Diagnostic Biomarkers to Detect Specific Stages of Ovarian Cancer: A Comprehensive Meta-Analysis.循环微小RNA作为检测卵巢癌特定阶段的诊断生物标志物:一项综合荟萃分析。
Cancers (Basel). 2024 Dec 16;16(24):4190. doi: 10.3390/cancers16244190.
2
MicroRNA targeting: A novel therapeutic intervention for ovarian cancer.微小RNA靶向作用:卵巢癌的一种新型治疗干预手段
Biochem Biophys Rep. 2023 Jul 24;35:101519. doi: 10.1016/j.bbrep.2023.101519. eCollection 2023 Sep.
3
MicroRNAs as Potential Biomarkers in Gynecological Cancers.
微小RNA作为妇科癌症的潜在生物标志物
Biomedicines. 2023 Jun 13;11(6):1704. doi: 10.3390/biomedicines11061704.
4
NPHS2-6 drives cervical squamous cell carcinoma (CSCC) progression via hsa-miR-1323/SMC1B axis to activate PI3K-Akt pathway.NPHS2-6 通过 hsa-miR-1323/SMC1B 轴驱动宫颈鳞状细胞癌(CSCC)进展,从而激活 PI3K-Akt 通路。
Clin Transl Oncol. 2024 Jan;26(1):245-259. doi: 10.1007/s12094-023-03248-9. Epub 2023 Jun 15.
5
Circulating microRNAs for Early Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis.循环 microRNAs 用于卵巢癌的早期诊断:系统评价和荟萃分析。
Biomolecules. 2023 May 22;13(5):871. doi: 10.3390/biom13050871.
6
Comparative Analysis of Transcriptomic Changes including mRNA and microRNA Expression Induced by the Xenoestrogens Zearalenone and Bisphenol A in Human Ovarian Cells.比较分析黄曲霉毒素和双酚 A 诱导人卵巢细胞的转录组变化,包括 mRNA 和 microRNA 表达。
Toxins (Basel). 2023 Feb 9;15(2):140. doi: 10.3390/toxins15020140.
7
Suppressing the PI3K/AKT Pathway by miR-30d-5p Mimic Sensitizes Ovarian Cancer Cells to Cell Death Induced by High-Dose Estrogen.通过miR-30d-5p模拟物抑制PI3K/AKT信号通路可使卵巢癌细胞对高剂量雌激素诱导的细胞死亡敏感。
Biomedicines. 2022 Aug 24;10(9):2060. doi: 10.3390/biomedicines10092060.
8
Revisiting the miR-200 Family: A Clan of Five Siblings with Essential Roles in Development and Disease.重新审视 miR-200 家族:五兄妹在发育和疾病中的关键作用。
Biomolecules. 2022 Jun 3;12(6):781. doi: 10.3390/biom12060781.
9
The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies.微小RNA在液体活检中作为诊断和预后生物标志物的作用。
Cancer Drug Resist. 2020 Feb 21;3(2):117-139. doi: 10.20517/cdr.2019.103. eCollection 2020.
10
Circulating non-coding RNAs in recurrent and metastatic ovarian cancer.复发性和转移性卵巢癌中的循环非编码RNA
Cancer Drug Resist. 2019 Sep 19;2(3):399-418. doi: 10.20517/cdr.2019.51. eCollection 2019.